Cardinal Health (CAH) Q1 2027 Earnings
Non-GAAP EPS excludes amortization and other acquisition-related costs of $182 million ($0.57/share), acquisition-related cash and share-based compensation costs of $94 million ($0.38/share), restructuring of $23 million ($0.07/share), and a $47 million litigation recovery ($(0.13)/share); GAAP diluted EPS was $2.38
How Did CAH Stock React to Q1 2027 Earnings?
Did CAH Beat Earnings? Q1 2027 Results
Yes. Cardinal Health reported Q1 2027 earnings of $3.26 a share on Nov 5, 2026, beating the $2.94 consensus estimate by 10.9%. Revenue was $67.5B against a $66.5B estimate.
Cardinal Health opened fiscal 2027 with a strong first quarter, posting adjusted non-GAAP EPS of $3.26 against a consensus estimate of $2.94, a 10.91% beat that extended the company's streak of beating EPS expectations to four consecutive quarters. Revenue of $67.51 billion topped estimates of $66.51 billion by 1.51% and grew 5.5% year over year, driven primarily by the Pharmaceutical and Specialty Solutions segment, where profit climbed 17% to $783.00 million as brand and specialty pharmaceutical sales from existing customers gained momentum and the generics program performed well. Non-GAAP EPS grew 28% overall, aided by a lower share count and a non-GAAP effective tax rate that fell to 18.5% from 21.9% a year ago. The company also announced a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health, reinforcing its core distribution franchise. Buoyed by the results, Cardinal raised its fiscal 2027 non-GAAP EPS guidance to $12.80 to $13.00, implying growth of 17% to 19% against its ex-tariff refund baseline, with the Pharmaceutical and Specialty Solutions segment profit growth target lifted to 10% to 12%.
- Brand and specialty pharmaceutical sales growth from existing customers
- Positive generics program performance
- Growth in Cardinal Health Brand products
- Growth across Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics
- Lower share count and lower effective tax rate boosted EPS
- Unfavorable distribution and foreign exchange impacts weighed on GMPD profit
“Our results reflect a strong start to fiscal 2027 and demonstrate consistent execution against our strategic priorities.”
Cardinal Health CEO, on the earnings call
What Is Cardinal Health's Outlook?
Cardinal Health raised its fiscal 2027 non-GAAP diluted EPS guidance to $12.80–$13.00, from $12.40–$12.60. - **Implied growth:** 17%–19% versus the FY26 ex-tariff refund baseline of $10.95, and 14%–15% versus reported FY26 results. - **Pharmaceutical and Specialty Solutions:** profit growth raised to 10%–12%, from 8%–11%. - **Other:** profit growth raised to 17%–20%, from 15%–18%. Revenue growth raised to 12%–14%, from 11%–13%. - **Tax rate:** non-GAAP effective tax rate lowered to 18.5%–19.5%, from 19.0%–20.0%. - **Share count:** diluted weighted average shares of 231–232 million, from about 233 million, reflecting the timing of the $500 million accelerated share repurchase.
CAH YoY Financials
| Metric | Q1 2027 | Q1 2026 | Year over year |
|---|---|---|---|
| Revenue | $67.5B | $64.0B | +5.5% |
| Gross Profit | $2.6B | $2.3B | +11.9% |
| Operating Income | $753.0M | $668.0M | +12.7% |
| Net Income | $554.0M | $450.0M | +23.1% |
CAH Revenue by Segment
When Does Cardinal Health Report Next?
Figures from SEC filings and company reports. Not investment advice.